Suppr超能文献

口服帕立骨化醇与口服骨化三醇治疗持续性非卧床腹膜透析继发性甲状旁腺功能亢进患者的疗效比较

Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.

作者信息

Jamaluddin Ema J, Gafor Abdul Halim Abdul, Yean Loo Chee, Cader Rizna, Mohd Rozita, Kong Norella C T, Shah Shamsul Azhar

机构信息

Nephrology Unit, Department of Medicine, University Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000, Cheras, Kuala Lumpur, Malaysia.

出版信息

Clin Exp Nephrol. 2014 Jun;18(3):507-14. doi: 10.1007/s10157-013-0844-2. Epub 2013 Aug 2.

Abstract

BACKGROUND

Secondary hyperparathyroidism (SHPT) is common in end-stage renal disease. Our primary objective was to evaluate the efficacy of oral paricalcitol versus oral calcitriol on serum intact parathyroid hormone (iPTH) and mineral bone parameters in continuous ambulatory peritoneal dialysis (CAPD) patients with SHPT. The secondary objective was to analyze highly sensitive C-reactive protein (hsCRP) and peritoneal membrane function in both groups.

METHODS

This was a prospective randomized control trial. CAPD patients with SHPT were randomized to paricalcitol or calcitriol for 15 weeks. Serum intact iPTH, calcium, phosphate and alkaline phosphatase (ALP) were measured at baseline and every 3 weeks. Serum hsCRP and peritoneal membrane functions were measured at baseline and at week 15.

RESULTS

A total of 26 patients were enrolled and randomized-12 to paricalcitol and 14 to calcitriol. Serum iPTH reduced significantly in both groups and there was no difference in the incidence of ≥50 % reduction of iPTH between both groups. There was a significant increase in serum calcium in both groups but there were no differences in serum phosphorus across the visits. The incidence of hypercalcemia was the same in both groups. Serum calcium-phosphorus (Ca × P) product increased in the paricalcitol group but decreased in the calcitriol group. Serum ALP decreased significantly in both groups. There were also no differences in pre- and post-treatment serum hsCRP and peritoneal function test (PFT) in both groups.

CONCLUSION

Both oral paricalcitol and calcitriol were equally efficacious in reducing serum iPTH but were associated with significantly higher serum calcium. Serum Ca × P product increased in the paricalcitol group and decreased in the calcitriol group. Serum hsCRP level and PFT were not affected by either treatment. A larger randomized controlled trial is indicated to confirm these initial findings.

摘要

背景

继发性甲状旁腺功能亢进(SHPT)在终末期肾病中很常见。我们的主要目标是评估口服帕立骨化醇与骨化三醇对持续性非卧床腹膜透析(CAPD)合并SHPT患者血清全段甲状旁腺激素(iPTH)及矿物质骨参数的疗效。次要目标是分析两组患者的高敏C反应蛋白(hsCRP)及腹膜功能。

方法

这是一项前瞻性随机对照试验。将CAPD合并SHPT的患者随机分为帕立骨化醇组或骨化三醇组,治疗15周。在基线及每3周时测定血清全段iPTH、钙、磷及碱性磷酸酶(ALP)。在基线及第15周时测定血清hsCRP及腹膜功能。

结果

共纳入26例患者并随机分组,12例接受帕立骨化醇治疗,14例接受骨化三醇治疗。两组患者血清iPTH均显著降低,且两组间iPTH降低≥50%的发生率无差异。两组患者血清钙均显著升高,但各次访视时血清磷无差异。两组高钙血症的发生率相同。帕立骨化醇组血清钙磷(Ca×P)乘积升高,而骨化三醇组降低。两组患者血清ALP均显著降低。两组治疗前后血清hsCRP及腹膜功能试验(PFT)也无差异。

结论

口服帕立骨化醇和骨化三醇在降低血清iPTH方面同样有效,但均伴有血清钙显著升高。帕立骨化醇组血清Ca×P乘积升高,骨化三醇组降低。血清hsCRP水平及PFT均不受两种治疗的影响。需要进行更大规模的随机对照试验来证实这些初步发现。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验